Experimental therapy offers hope for kids with tough leukemia

NCT ID NCT07078929

First seen Mar 18, 2026 · Last updated May 14, 2026 · Updated 6 times

Summary

This early-stage trial tests a new type of cell therapy (CMD63) in 16 children whose B-cell leukemia has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better target and kill cancer cells. The main goal is to check safety, but researchers will also see if it helps control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSE B ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • King Chulalongkorn Memorial Hospital

    RECRUITING

    Bangkok, Pathumwan, 10330, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Maharaj Nakorn Chiang Mai Hospital

    NOT_YET_RECRUITING

    Chiang Mai, Mueang Chiang Mai District, 50200, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Siriraj Hospital

    NOT_YET_RECRUITING

    Bangkok, Bangkoknoi, 10700, Thailand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.